Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders

a neurodegenerative and other neurological disorder technology, applied in the field of biochemical and biological compositions, can solve the problems of harmful inflammatory consequences, sensitive enough to detect apoptosis,

Inactive Publication Date: 2007-04-19
VASOGEN IRELAND LTD
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about the discovery that giving mammals cells that have been programmed to die can help prevent or treat neurological disorders. The cells are made into a pharmaceutical composition that can be injected into patients. The composition is made with a safe substance and can help protect the cells from damage during injection. The method of treatment involves giving the patient the pharmaceutical composition to help prevent or treat the neurological disorder.

Problems solved by technology

The appearance of DNA laddering on agarose gel electrophoresis following extraction of DNA from cells is one recognised method of identification of apoptosis in cells [Loo, D. T. and Rillema, J. R. (1998) “Measurement of Cell Death,”Methods in Cell Biology 57: 251-264], although it is not always sensitive enough to detect apoptosis.
Necrosis, in contrast, is cell death of a pathological nature, resulting from injury, bacterial toxin effects, inflammatory mediators, etc., and involving membrane rupture and release of intracellular contents to the surrounding tissue, often with harmful inflammatory consequences.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
  • Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0042] Experiments to demonstrate the invention were conducted on laboratory mice, under approved conditions for conducting such experiments.

[0043] The effectiveness of the treatment according to a preferred embodiment of the present invention, on contact hypersensitivity (CHS), an example of a Th-1-cell inflammatory disorder which is known to be mediated by inflammatory cytokines, was assessed on laboratory mice, according to approved animal experimentation procedures, using the method described by Kondo et. al., “Lymphocyte function associated antigen-1 (LFA-1) is required for maximum elicitation of allergic contact dematitis” Br. J. Dermatol. 131:354-359 (1994), with minor variations. The disclosure thereof is incorporated herein by reference. Briefly, to induce C H S, the abdominal skin of each mouse was shaved and painted with dinitrodifluorobenzene DNFB, the sensitizing chemical, using 25 μl of 0.5% DNFB in 4:1 acetone:olive oil solution. This sensitization was applied to two...

example 2

[0049] The above test procedure was repeated on similar groups of animals, a control group and a test group, but using a suspension of apoptotic cells and bodies on the test group which comprised about 60% apoptotic cells and bodies, balance viable cells and a minor amount (not more than 20%) of necrotic cells. Essentially similar results were obtained.

[0050] The effectiveness of the processes and compositions of the present invention in preventing and alleviating inflammation due to CHS indicates that administration of apoptotic cells and bodies as described up-regulates the in vivo generation of anti-inflammatory Th-2 derived cytokines such as IL-10 (known to be implicated in CHS—see Kondo, McKenzie and Sauder, “The Journal of Investigative Dermatology,” Vol. 103, 1994, page 811-814) and / or down-regulates Th-1 inflammatory cytokines such as TNFα and IL-6. These inflammatory cytokines are implicated in inflammation-related disorders of the brain, namely the neuroinflammatory, neur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weight percentaaaaaaaaaa
weight percentaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

Treatment and / or prophylaxis, in mammalian patients, of neurodegenerative and other neurological medical disorders is effected by administering to the patient effective amounts of apoptotic bodies and / or apoptotic cells, preferably those derived from the patient's own white blood cells, e.g. by extracorporeal treatment of the patient's blood cells to induce apoptosis and administration of the apoptotic bodies and / or cells so formed to the patient.

Description

FIELD OF THE INVENTION [0001] This invention relates to biochemical and biological compositions and to the uses thereof in the treatment and / or prophylaxis of various neurodegenerative and other neurological disorders in mammalian patients. More particularly, it relates to treatment and prophylaxis of neurodegenerative and other neurological disorders by administration of compositions containing the mammalian cellular materials and fragments thereof, and to the compositions containing the mammalian cellular materials and fragments themselves, and to processes for preparing such compositions. BACKGROUND OF THE INVENTION [0002] Two mechanisms of cell death in the body are recognized, necrosis and apoptosis. Apoptosis is the process of programmed cell death, described by Kerr et al in 1992 [Kerr J F R, Wyllie A H, Currie A R (1992). “Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. “British Journal of Cancer 26: 239-257”], by which steady-stat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00C12N5/08A61K35/17A01N65/00A61K35/14A61P21/04A61P25/00A61P25/02A61P25/14A61P25/16A61P25/24A61P25/28A61P37/00
CPCA01N65/00A61K35/17A01N2300/00A61P21/04A61P25/00A61P25/02A61P25/14A61P25/16A61P25/24A61P25/28A61P37/00A61K39/461A61K39/46432A61K2239/31A61K2239/38
Inventor BOLTON, ANTHONY E.MANDEL, ARKADYSAUDER, DANIEL
Owner VASOGEN IRELAND LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com